



New CyberKnife® System Data Presented at Leading Scientific Industry Meeting

Studies of the InCise™ Multileaf Collimator (MLC) for the CyberKnife M6™ System Reinforce its Accuracy, Reliability and Precise Dose Delivery

SUNNYVALE, Calif., July 14, 2015 – Accuray Incorporated (Nasdaq: ARAY) announced today that studies on the clinical use of the CyberKnife® System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques. More than 30 studies were presented during poster and oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Anaheim, California, July 12 – July 16, 2015.

For more information on the CyberKnife System, visit <http://www accuray.com/solutions/treatment-planning/cyberknife-treatment-planning-system>.

Leading academic institutions, hospitals and cancer treatment centers are adopting the **MLC technology and seeing its benefits in significantly reduced treatment times for a wider range of tumor types**. UPMC CancerCenter, Erasmus MC Cancer Institute and European CyberKnife Center Munich shared the first presented results on the use of the InCise™ MLC for the CyberKnife M6™ System. These results showed the device was:

- **“Very reliable”**
- **“Highly accurate”**
- **“Mechanically stable”**

Studies continue to validate CyberKnife System’s unparalleled tumor targeting capabilities. Highlights include:

Two dosimetric studies highlight the CyberKnife System’s precision.

- A study undertaken at UT Southwestern Medical Center compared the CyberKnife System and linac IMRT plans of patients with early-stage larynx cancer. Researchers found the CyberKnife System was better able to reduce the radiation dose to normal tissue in high-dose regions. Clinicians can have the confidence to deliver an ablative dose to the tumor while sparing the immediately adjacent organs at risk.
- A second study showed the CyberKnife Multiplan® treatment planning system provided better dose conformity and less dose to critical organs than VMAT stereotactic plans for patients with localized prostate cancer. The data demonstrated radiation dose delivery via multiple non-coplanar beams, with the CyberKnife System leads to unrivaled precision and tissue sparing. This research was conducted at Medanta - The Medicity hospital in Gurgaon, Haryana.

“Data presented at AAPM reinforce the benefits of the CyberKnife System’s non-coplanar beam delivery in ensuring maximal dose distribution precision while minimizing dose to surrounding healthy tissue and organs,” said Calvin Maurer, Ph.D., vice president and chief technology officer at Accuray. “With the addition of the MLC, clinicians can administer these precise treatments to a broader range of patients significantly faster. The real-world results clinicians are achieving with the MLC are consistent with those seen in the technical evaluation site experience reported at AAPM.”

Educational Event

Accuray hosted an educational symposium titled, "Precision in Practice™ with Accuray Technology" featuring Martina Descovich, Ph.D., Assistant Professor, Division of Physics, Department of Radiation Oncology at UCSF in San Francisco, California, and Saiful Huq, Ph.D., DABR, FAAPM, FInstP, Professor and Director of Medical Physics, Department of Radiation Oncology at UPMC CancerCenter in Pittsburgh, Pennsylvania, in addition to two invited presenters on the TomoTherapy® System. Dr. Descovich discussed the center's clinical experience with an enhanced Synchrony® Respiratory Tracking System on the CyberKnife® System and Dr. Huq shared UPMC's experience with the InCise™ MLC.

About the CyberKnife System

The CyberKnife M6™ Series delivers radiosurgery and stereotactic body radiation therapy, enabling precise, high-quality dose distributions to be administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The system is able to adjust and automatically stay on target in real-time, accounting for patient and tumor motion continually throughout the treatment. CyberKnife is the only robotic radiosurgery system available today which delivers such high precision treatments for intra- and extra-cranial disease sites throughout the body.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, market adoption of the company's products, including the MLC, and Accuray's leadership position radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's reports on Form 10-Q, filed on November 7, 2014, February 6, 2015 and May 7, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

###

Contact:

Beth Kaplan

Accuray

+1 (408) 789-4426

bkaplan@accuray.com

Kirsten Fallon

MSLGROUP in Boston

+1 (781) 684-0770

Kirsten.Fallon@MSLGROUP.com